Adaptimmune Therapeutics Plc SEC Filings

Adaptimmune Therapeutics plc reporting person William C. Bertrand, Jr., who is Chief Operating Officer and a director, disclosed the sale of 207,000 ordinary shares (represented by 34,500 ADSs) on 08/28/2025 at an ADS sale price of $0.0603 (equivalent to $0.01005 per ordinary share). After the reported sale he beneficially owns 986,352 ordinary shares (164,392 ADSs). The filing states he also holds RSU-style options and other options covering an aggregate of 16,108,722 ordinary shares. The Form 4 is signed 08/29/2025 and indicates the securities sold were ADSs representing ordinary shares.

Adaptimmune Therapeutics plc (ADAP) Form 144 notice reports a proposed sale of 34,500 American Depositary Shares (ADS) executed through ETrade by Morgan Stanley with an approximate sale date of 08/28/2025 on Nasdaq. The filing shows an aggregate market value of $2,070 for the shares and lists 256,032,610 shares outstanding. The securities were acquired in an open-market purchase on 12/14/2020 for cash by the person filing, and no securities were reported sold in the prior three months. Several filer and issuer identification fields in the document are left blank in the provided content.

Adaptimmune insider sales by a director reduced his indirect holdings to zero. Ali Behbahani, a director and manager of entities holding shares, reported two dispositions of Adaptimmune ordinary shares represented by ADSs. On 08/15/2025 he reported sale of 4,828,206 ordinary shares at a weighted average price of $0.011 per share, leaving 14,671,794 shares indirectly owned. On 08/18/2025 he reported sale of 14,671,794 ordinary shares at a weighted average price of $0.012 per share, resulting in zero indirect beneficial ownership. The filings state these ordinary shares were held as ADSs by NEA 16 and explain price ranges and ownership through NEA entities.

This Amendment No. 3 to the Schedule 13D updates prior filings by New Enterprise Associates-related reporting persons concerning Adaptimmune Therapeutics Plc ordinary shares. Collectively the reporting persons hold 4 Ordinary Shares (the "Firm Shares"), which the filing states represents 0% of the class based on 1,590,309,546 Ordinary Shares outstanding. The filing discloses shared voting and dispositive power over those 4 shares and identifies the funds, control entities and individual managers involved. The Amendment attaches Schedule A for recent transactions and cites Exhibit 1 (joint filing agreement) and Exhibit 3 (power of attorney).

EcoR1 Capital, Oleg Nodelman and an EcoR1 fund report joint beneficial ownership of Adaptimmune Therapeutics plc ordinary shares. The filing shows EcoR1 Capital and Mr. Nodelman each have shared voting and dispositive power over 66,000,000 ordinary shares (representing 4.2% of the class), while EcoR1 Capital Fund Qualified, L.P. holds shared power over 63,184,650 ordinary shares (representing 4.0% of the class). The shares are held through American Depositary Shares (11,000,000 ADS for EcoR1/ Nodelman; 10,530,775 ADS for the Qualified Fund), with each ADS representing six ordinary shares. Percentages are calculated using 1,590,309,546 ordinary shares outstanding as of August 11, 2025. The filing states the positions were acquired in the ordinary course of business and not to influence control.

Form 144 notice for Adaptimmune Therapeutics plc (ADAP): A proposed sale of 13,829,778 American Depositary Receipts is being submitted for sale through J.P. Morgan Securities LLC on or about 08/15/2025 on NASDAQ. The form lists the issuer's total shares outstanding as 1,590,309,546 and reports an aggregate market value for the proposed sale of 981,914. The ADRs were acquired in private placements from the issuer on several dates between 09/23/2014 and 09/05/2018, with recorded quantities for each acquisition and cash as the nature of payment. No securities were reported sold by the filer in the past three months. The filer certifies they are not aware of undisclosed material adverse information.

Form 144 notice: The filer notified the sale of 3,250,000 American Depositary Receipts (ADRs) through J.P. Morgan Securities LLC with an approximate aggregate market value of $230,750, and an approximate sale date of 08/15/2025 on NASDAQ. The filing reports 1,590,309,546 ADRs outstanding. The securities were originally acquired in private placements from the issuer on 09/05/2018 (2,000,000 ADRs) and 01/22/2020 (1,250,000 ADRs), with payment in cash on the acquisition dates. The filer certifies they have no undisclosed material adverse information. The filing shows no securities sold by the seller in the past three months.